Bonesupport Holding Ab · OMXSTO:BONEX
Bonesupport Holding Ab — Q2 2022 Earnings Presentation
15 slides from Bonesupport Holding Ab's earnings presentation, Jul 14, 2022
Slide 1: Q2 (2022) Report
BONESUPPORT Q2 (2022) Report July 14th , 2022 Emil Billbäck, CEO Håkan Johansson, CFO
Slide 2: Disclaimer
DISCLAIMER This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to BONESUPPORT HOLDIN
Slide 3: Second quarter report 2022
BONESUPPORT – Second quarter report 2022 Q2 2022: • Net sales SEK 74,6 m, growth: 44% versus Q2 2021, +32% in constant exchange rates (CER) • EBIT: SEK -14,9 m (-26,0 m): a SEK 13.6 m profit improvement before incentive provisions • FDA marketing approval in the US for CERAMENT G (Gentamicin) • CMS
Slide 4: Eight consecutive all-time-high, strong traction in both regions
Eight consecutive all-time-high, strong traction in both regions LTM Quarterly Sales per Segment 275.0 275.0 257 250.0 250.0 Rapidly expanding 234 customer base and 225.0 213 225.0 broadened use of 205 CERAMENT 197 200.0 200.0 180 181 Transition in U.S. 173 175.0 166165 175.0 distributor 155 Net Sal
Slide 5: North America: Strong sales growth in Q2, advancing market positions
North America: Strong sales growth in Q2, advancing market positions Q2 2022 • Sales of SEK 46,0 m, growth of 58% over Q2 2021, +40% in constant exchange rate • Sales in Q2 represented a reported sequential growth of 14% over Q1 2022 and +32% over Q4 2021 Expanding customer base • First patients wit
Slide 6: EUROW: Gradual return of surgical volumes, restricted by staff shortages
EUROW Gradual return of surgical volumes, restricted by Healthcare staff shortages Q2 2022 • Sales of SEK 28,6 m, growth of 26% vs Q2 2021, +22% in constant exchange rates • Some hospital still with restrictions to visit. • Safety protocol and healthcare staff shortage are holding back surgery capac
Slide 7: Financial Report
BONESUPPORT Q2 (2022) Report Financial Report
Slide 8: Q2 2022 net sales SEK 74.6 m
Q2 2022 net sales SEK 74.6 m • 58 percent growth in NA. 40 percent growth in CER • 26 percent reported growth in EUROW. 22 percent growth CER • High impact from currency movements 8
Slide 9: North America and EUROW net sales and gross margin
North America +58% EUROW +26% (+40% CER) (+22% CER) Net sales Net sales Q2-22 Q2-22 North America 2022 2021 EUROW 2022 2021 SEK m Q2-22 Q1-22 Q4-21 Q3-21 Q2-21 SEK m Q2-22 Q1-22 Q4-21 Q3-21 Q2-21 Net Sales 46.0 41.2 34.8 32.7 29.1 Net Sales 28.6 25.2 26.6 22.2 22.7 Gross profit 42.9 38.6 32.7 30.6 2
Slide 10: A 13.6 MSEK profit improvement before long-term incentive provisions
A 13.6 MSEK profit improvement before long-term incentive provisions Key Figures 2022 2021 2020 SEK m Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Net Sales 74.6 66.3 61.4 54.9 51.8 44.8 53.2 48.1 36.2 Gross Margin (%) 89.0% 90.5 89.3 89.0 89.5 88.6 89.8 91.4 86.7 Operating Loss -14.7 -16.5 -21.8 -13.3 -25.9 -19.7 -2
Slide 11: Q2 expenses approaching a post pandemic normal
Q2 expenses approaching a post pandemic normal Key Figures 2022 2021 2020 SEK m Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Selling expenses (less commissions) 40.4 37.5 38.5 35.5 33.3 31.2 33.9 32.0 23.0 Sales Commissions 14.2 12.9 11.4 10.0 9.3 7.9 8.4 9.2 6.9 Research and Development expenses 13.8 12.1 14.4 11.3
Slide 12: Clear Corporate Strategy Driving Value Creation
BONESUPPORT Q2 (2022) Report Clear Corporate Strategy Driving Value Creation
Slide 13: Journey ahead - near term milestones
BONESUPPORT journey ahead - near term milestones October 2022: US Launch CERAMENT G Q2 2022: Q1 2024: Health Economic model Q1 2023: SOLARIO study finished. European bone infection U.S. SOLARIO Last efficacy and safety study on 500 patients patient in randomized to SOC or CERAMENT G 2021 2022 2023 2
Slide 14: Ramping up for US CERAMENT G launch, with strong dynamics in existing business
Ramping up for US CERAMENT G launch, with strong dynamics in existing business • CERAMENT G (Gentamicin) is the first ever synthetic bone graft with antibiotics approved by FDA – Only product in new category addressing a market opportunity of USD 780 m – Strong and well-developed US commercial infra
Slide 15: Q&A
BONESUPPORT Q2 (2022) Report Q&A